What is HC Wainwright’s Estimate for DVAX Q2 Earnings?

Dynavax Technologies Co. (NASDAQ:DVAX) – Stock analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Dynavax Technologies in a research note issued on Tuesday, January 14th. HC Wainwright analyst E. White forecasts that the biopharmaceutical company will post earnings of $0.08 per share for the quarter. HC Wainwright has a “Buy” rating and a $31.00 price objective on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share. HC Wainwright also issued estimates for Dynavax Technologies’ Q3 2025 earnings at $0.12 EPS, FY2025 earnings at $0.35 EPS and FY2026 earnings at $0.45 EPS.

Separately, StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $12.48 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a market cap of $1.64 billion, a P/E ratio of 96.01 and a beta of 1.34. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.41. The firm’s 50 day simple moving average is $12.77 and its 200-day simple moving average is $11.66.

Hedge Funds Weigh In On Dynavax Technologies

A number of large investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its position in Dynavax Technologies by 2.2% during the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock valued at $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Great Point Partners LLC grew its holdings in shares of Dynavax Technologies by 87.7% during the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after acquiring an additional 1,109,080 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Dynavax Technologies during the 2nd quarter valued at $17,615,000. Mizuho Markets Americas LLC increased its stake in shares of Dynavax Technologies by 17.4% in the third quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after acquiring an additional 204,475 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Dynavax Technologies by 8.3% during the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after acquiring an additional 82,449 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.